SARS-CoV-2 mRNA Vaccine Effectiveness in the Borriana COVID-19 Cohort: A Prospective Population-Based Cohort Study
Authors:
- Salvador Domènech-MontoliuSDSalvador Domènech-Montoliu
- Óscar Pérez-OlasoÓPÓscar Pérez-Olaso
- Diego Sala-TrullDSDiego Sala-Trull
- Alba Del Rio-GonzalezARAlba Del Rio-Gonzalez
- Laura López-DiagoLLLaura López-Diago
- Isabel Aleixandre-GorrizIAIsabel Aleixandre-Gorriz
- Maria Rosario Pac-SaMPMaria Rosario Pac-Sa
- Manuel Sánchez-UrbanoManuel Sánchez-Urbano
- Paloma Sarorres-MartinezPSPaloma Sarorres-Martinez
- Cristina Notari-RodriguezCNCristina Notari-Rodriguez
- Juan Casanova-SuárezJCJuan Casanova-Suárez
- Raquel Ruiz-PuigRRRaquel Ruiz-Puig
Preprint
- 4 November 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Evaluation of vaccine effectiveness (VE) was essential to implement strategies of prevention, and our objective was estimated the VE of SARS-CoV-2 messenger RNA (mRNA) vaccines to prevent SARS-CoV-2 infection. We performed a population-based prospective cohort study in the Borriana COVID-19 cohort (Valencia Community, Spain) during the period 2021-2023, with two approaches, considering firstly, all cases occurred after SARS-CoV-2 vaccine campaign started in January 2021, and then secondly, only symptomatic cases. Multivariable robust Poisson regression models were employed. Results: In first approach, of 301 participants, 285 were vaccinated, 228 with only SARS-CoV-2 mRNA vaccines, and 57 with mRNA vaccine and other vaccines. A total of 226 cases occurred with 75 non-cases. Adjusted VE for 3 doses of vaccine received was 37% (95% Confidence interval [CI] 22%-49%). The second approach, with 153 symptomatic cases, excluding 73 asymptomatic cases, adjusted VE for 3 doses of vaccine received was 50% (95% CI 33%-63%). While one or two doses of vaccines presented a low VE with insufficient to protect against infection, 3 doses of vaccine reached modest and significant protection. Exclusion of asymptomatic cases improved the VE estimation. Conclusion: Development of new vaccines is needed to improve control and prevention strategies against SARS-CoV-2.Keywords
All Related Versions
- Version 1, 2025-11-04, Preprints
- Published version: Epidemiologia, 7 (1), 1.
This publication has 47 references indexed in Scilit:
- Association of protective behaviors with SARS-CoV-2 infection: results from a longitudinal cohort study of adults in the San Francisco Bay AreaAnnals of Epidemiology, 2023
- Effectiveness of the booster dose of COVID-19 vaccine in the Basque Country during the sixth wave: A nationwide cohort studyVaccine, 2023
- Effectiveness of mRNA vaccine against Omicron-related infections in the real world: A systematic review and meta-analysisAmerican Journal of Infection Control, 2023
- Effect of COVID-19 vaccination on the SARS-CoV-2 transmission among social and household close contacts: A cohort studyJournal of Infection and Public Health, 2023
- Effectiveness of messenger RNA vaccines against infection with SARS-CoV-2 during the periods of Delta and Omicron variant predominance in Japan: the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) studyInternational Journal of Infectious Diseases, 2022
- Transmission and Infectious SARS-CoV-2 Shedding Kinetics in Vaccinated and Unvaccinated IndividualsJAMA Network Open, 2022
- Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regressionThe Lancet, 2022
- Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort studyThe Lancet Infectious Diseases, 2022
- Estimating the reproductive number R0 of SARS-CoV-2 in the United States and eight European countries and implications for vaccinationJournal of Theoretical Biology, 2021
- Comparison of the Elecsys® Anti-SARS-CoV-2 immunoassay with the EDI™ enzyme linked immunosorbent assays for the detection of SARS-CoV-2 antibodies in human plasmaClinica Chimica Acta, 2020